Advancements in MS Treatment: New Gadolinium Agent, Myelin, and High-Efficacy DMTs

TL;DR
A Phase 3 clinical trial will test a new gadolinium-based MRI contrast agent, gadoquatrane, which uses a dose that is 60% lower than other agents, potentially addressing concerns about kidney problems. Research suggests that myelin-coated nerves may be more vulnerable to inflammatory damage than uncoated ones, opening new avenues for multiple sclerosis (MS) treatment. A study recommends starting MS treatment with high-efficacy disease-modifying therapies (DMTs) to achieve better outcomes, challenging the practice of prescribing less-effective DMTs as first-line treatments.
Topics:healthmedical-research#disease-modifying-therapy#medical-research#mri-contrast-agent#ms-treatment#multiple-sclerosis#myelin
MS news notes: New gadolinium agent, myelin, high-efficacy DMTs –... Multiple Sclerosis News Today
Want the full story? Read the original reporting
Read on Multiple Sclerosis News Today